ID   OMC-1 [Human cervical carcinoma]
AC   CVCL_1623
SY   OMC1; Osaka Medical College-1
DR   CLO; CLO_0050939
DR   ArrayExpress; E-MTAB-783
DR   BioSample; SAMN03472225
DR   cancercelllines; CVCL_1623
DR   Cell_Model_Passport; SIDM00240
DR   ChEMBL-Cells; CHEMBL3308213
DR   ChEMBL-Targets; CHEMBL2366339
DR   Cosmic; 949154
DR   Cosmic; 1152541
DR   Cosmic; 1995602
DR   Cosmic-CLP; 949154
DR   DepMap; ACH-002180
DR   GDSC; 949154
DR   GEO; GSM1670305
DR   IARC_TP53; 27570
DR   LINCS_LDP; LCL-1546
DR   PharmacoDB; OMC1_1199_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1623
DR   RCB; RCB0753
DR   Wikidata; Q54932030
RX   DOI=10.1267/ahc.26.515;
RX   PubMed=2486664;
RX   PubMed=2531191;
RX   PubMed=3746026;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 43 hours (Note=At 15th passage) (PubMed=2486664).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=76.41%; East Asian, South=22.8%; South Asian=0%; European, North=0.62%; European, South=0.16% (PubMed=30894373).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
ST   Source(s): Cosmic-CLP; RCB
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 8,12
ST   D16S539: 11,12
ST   D5S818: 10,11
ST   D7S820: 11,12
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 16,17
DI   NCIt; C180839; Cervical squamous cell carcinoma, not otherwise specified
DI   ORDO; Orphanet_213767; Squamous cell carcinoma of the cervix uteri
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 36
//
RX   DOI=10.1267/ahc.26.515;
RA   Tsuchida K., Okamoto Y., Yamada T., Ueda M., Iijima J., Shiina Y.,
RA   Hirano H., Rokukawa C., Kasama T., Taki T., Handa S., Ueki M.,
RA   Adachi K.;
RT   "Discrimination of metastatic cells from mesothelial cells in effusion
RT   cytology by monoclonal antibody AD117m directed against
RT   lactotetraosylceramide.";
RL   Acta Histochem. Cytochem. 26:515-530(1993).
//
RX   PubMed=2486664;
RA   Ueda M., Ueki M., Yamada T., Okamoto Y., Maeda T., Sugimoto O.,
RA   Otsuki Y.;
RT   "Scatchard analysis of EGF receptor and effects of EGF on growth and
RT   TA-4 production of newly established uterine cervical cancer cell line
RT   (OMC-1).";
RL   Hum. Cell 2:401-410(1989).
//
RX   PubMed=2531191;
RA   Ueda M., Misaki O., Yamada T., Okamoto Y., Goto M., Maeda T.,
RA   Okamura S., Ueki M., Sugimoto O.;
RT   "In vitro studies of 5-FU sensitivity on uterine cervical cancer cell
RT   lines -- comparison between squamous cell carcinoma and
RT   adenocarcinoma.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 41:1423-1430(1989).
//
RX   PubMed=3746026;
RA   Ueda M., Maeda T., Yamada T., Miyawaki Y., Otsuki Y., Okamoto Y.,
RA   Okamura S., Sano T., Ueki M., Sugimoto O.;
RT   "Establishment and characterization of TA-4 producing cell line (OMC-1)
RT   originating from a human squamous cell carcinoma of the uterine cervix.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 38:1071-1078(1986).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//